

### **REMARKS**

Claims 1-11 were originally filed in the present application. In the Office Communication mailed February 24, 2004, The Examiner stated that the application disclosed/contained, in Claim 7 and Claim 10, respectively, the following patentably distinct species:

For Claim 7, the species are as follows:

Wherein the sugar chain-modifying enzyme is selected from:

- a)  $\alpha$ -1,2-mannosidase,
- b) mannosidase IA,
- c) mannosidase IB,
- d) mannosidase IC,
- e) mannosidase II,
- f) N-acetyl glucosaminyltransferase I
- g) N-acetylglucosaminyltransferase II,
- h) galactosyltransferase,
- i) sialyltransferase, and
- j) fucosyltransferase

For Claim 10, the species are as follows:

Wherein the recombinant glycoprotein is selected from:

- 1) cytokines,
- 2) clotting factors,
- 3) growth factors,
- 4) growth hormone releasing factors,
- 5) angiotatin,
- 6) tissue plasminogen activator,
- 7) plasminogen activator inhibitor,
- 8) urokinase,
- 9) *Bacillus amyloliquefaciens*  $\alpha$ -amylase,
- 10) *Saccharomyces cerevisiae* aspartic protease,
- 11) *Saccharomyces cerevisiae* invertase,

- 12) *Typanosoma cruzi* trans-sialidase,
- 13) HIV20 envelope protein,
- 14) haemagglutinin,
- 15) enterokinase,
- 16) human  $\alpha$ 1-antitrypsin,
- 17) human antithrombin III,
- 18) erythropoietin,
- 19) herpes virus type-1 glycoprotein, and
- 20) immunoglobulins

The Examiner directs Applicants to elect a single disclosed species from each group [(a)-(j) for Claim 7, and (1)-(20) for Claim 10) for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

In order to further their business interests and the prosecution of the present application, yet without acquiescing to the Examiner's arguments, Applicants herein elect, without traverse, the species  $\alpha$ -1,2-mannosidase in Claim 7. Claims 5-11 read on the elected species. Furthermore, applicants herein elect, without transverse, *Saccharomyces cerevisiae* invertase in Claim 10. Claims 5-11 read on the elected species.

### CONCLUSION

As such, Claims 1-11 are pending and under examination following entry of Applicants' response to the outstanding Species election requirement.

Respectfully submitted,

Dated: April 22, 2009

/Tanya A. Arensen/

Tanya A. Arensen  
Registration No. 47,391

CASIMIR JONES, S.C.  
440 Science Drive, Suite 203  
Madison, Wisconsin 53711  
608.218.6900